TheraRadar
Clinical-Stage Companies / Tibotec Pharmaceuticals, Ireland

Tibotec Pharmaceuticals, Ireland

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 11/1/2011

53
Total Trials
2
Phase 3
8
Phase 2
0
Recruiting
223
Score

Pipeline by Phase

Phase 3
2
Phase 2
8
Phase 1
43

Therapeutic Focus

Hepatitis C Hepatitis C Virus HIV HIV Infections HIV-1

Clinical Trials (53)

NCT00543725 Phase 3 COMPLETED

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Started: 6/1/2008

NCT00540449 Phase 3 COMPLETED

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Started: 5/1/2008

NCT00665847 Phase 2 COMPLETED

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

Started: 11/1/2008

NCT00812331 Phase 2 COMPLETED

A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)

Started: 3/1/2009

NCT00882908 Phase 2 COMPLETED

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Started: 6/1/2009

NCT00980330 Phase 2 COMPLETED

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

Started: 10/1/2009

NCT00561353 Phase 2 COMPLETED

A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

Started: 1/1/2008

NCT00919854 Phase 2 COMPLETED

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Started: 9/1/2009

NCT00838162 Phase 2 COMPLETED

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Started: 6/1/2009

NCT00915655 Phase 2 COMPLETED

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Started: 7/1/2009

NCT00908414 Phase 1 WITHDRAWN

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

Started: 5/1/2009

NCT01224197 Phase 1 COMPLETED

TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers

Started: 10/1/2010

NCT01308658 Phase 1 COMPLETED

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Started: 1/1/2011

NCT00915564 Phase 1 COMPLETED

A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone

Started: 9/1/2009

NCT01381835 Phase 1 COMPLETED

TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435

Started: 7/1/2011

NCT01046058 Phase 1 COMPLETED

TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

Started: 1/1/2010

NCT01052883 Phase 1 COMPLETED

TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

Started: 3/1/2010

NCT01269294 Phase 1 COMPLETED

TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Started: 1/1/2011

NCT01124799 Phase 1 COMPLETED

TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light

Started: 7/1/2010

NCT00741169 Phase 1 COMPLETED

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Started: 6/1/2008

NCT01134718 Phase 1 COMPLETED

TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration

Started: 6/1/2010

NCT01090700 Phase 1 COMPLETED

TMC435-TiDP16-C112 - Interaction Trial With Antidepressants

Started: 5/1/2010

NCT01288677 Phase 1 COMPLETED

TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers

Started: 1/1/2011

NCT01202825 Phase 1 COMPLETED

TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients

Started: 4/1/2010

NCT01486004 Phase 1 COMPLETED

A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen

Started: 11/1/2011

NCT01090648 Phase 1 COMPLETED

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

Started: 3/1/2010

NCT01288742 Phase 1 COMPLETED

TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin

Started: 1/1/2011

NCT01205139 Phase 1 COMPLETED

TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir

Started: 11/1/2010

NCT01031589 Phase 1 COMPLETED

TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

Started: 1/1/2010

NCT01241773 Phase 1 COMPLETED

TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

Started: 10/1/2010

NCT01479881 Phase 1 COMPLETED

A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

Started: 10/1/2011

NCT01308606 Phase 1 COMPLETED

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

Started: 3/1/2011

NCT01323257 Phase 1 COMPLETED

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

Started: 3/1/2011

NCT01336829 Phase 1 COMPLETED

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Started: 3/1/2011

NCT01288755 Phase 1 COMPLETED

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

Started: 2/1/2011

NCT00752310 Phase 1 COMPLETED

TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet

Started: 4/1/2008

NCT00767117 Phase 1 COMPLETED

TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.

Started: 9/1/2008

NCT00744809 Phase 1 COMPLETED

TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.

Started: 8/1/2008

NCT00812292 Phase 1 COMPLETED

TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation

Started: 1/1/2009

NCT00740389 Phase 1 COMPLETED

TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

Started: 9/1/2008

NCT00744887 Phase 1 COMPLETED

TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.

Started: 8/1/2008

NCT00828815 Phase 1 COMPLETED

TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.

Started: 3/1/2009

NCT00741741 Phase 1 TERMINATED

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

Started: 7/1/2008

NCT01001247 Phase 1 COMPLETED

TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers

Started: 1/1/2010

NCT01022125 Phase 1 COMPLETED

TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435

Started: 1/1/2010

NCT00866853 Phase 1 COMPLETED

TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.

Started: 3/1/2009

NCT00739622 Phase 1 COMPLETED

TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.

Started: 7/1/2008

NCT00736905 Phase 1 COMPLETED

TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.

Started: 6/1/2008

NCT00744770 Phase 1 COMPLETED

TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.

Started: 10/1/2008

NCT00854204 Phase 1 COMPLETED

Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629

Started: 11/1/2008

NCT00752544 Phase 1 COMPLETED

TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers

Started: 8/1/2008

NCT00838760 Phase 1 COMPLETED

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

Started: 2/1/2009

NCT00752648 Phase 1 COMPLETED

TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule

Started: 7/1/2008

Drug Candidates

TMC589337 40 mg TMC589337 100 mg TMC589337 200 mg TMC589337 400 mg TMC589354 40 mg TMC589354 100 mg TMC589354 200 mg TMC589354 400 mg TMC589337 AA mg TMC589354 BB mg
Activity Status: Inactive
Last Trial Started: 11/1/2011
Last Trial Ended: 2/1/2012
Trials (12 months): 0
Completed Trials: 51
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.